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 Background 
 WHO grade II and III gliomas comprise astrocytic, 
oligodendroglial and oligoastrocytic tumors, and repre-
sent a heterogeneous group of tumors regarding natural 
course, benefit from treatment, and prognosis. Surgery, 
radiotherapy and chemotherapy have a role in the treat-
ment of WHO grade II gliomas, but their sequence and 
timing remain controversial  [1] . Multimodal therapy in-
cluding surgery followed by radiotherapy or temozolo-
mide chemotherapy represents the current standard of 
care in most countries  [2] . At recurrence or failure of 
these standard therapeutic options, the repertoire of sal-
vage regimens is limited. Phase II chemotherapy trials in 
patients with recurrent anaplastic gliomas in the pre-te-
mozolomide era showed response rates in the range of 
14% and progression-free survival (PFS) rates at 6 months 
in the range of 31%  [3] . Bevacizumab (BEV) has shown 
activity as determined by response and PFS in recurrent 
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 Abstract 
 Background: The repertoire of salvage regimens for pa-
tients with WHO grade II and III gliomas recurring or pro-
gressing after surgery, radiotherapy and temozolomide che-
motherapy is limited. Based on promising response and pro-
gression-free survival (PFS) data in recurrent glioblastoma, 
the use of bevacizumab (BEV) has been extended to recur-
rent grade II/III gliomas.  Methods: We retrospectively as-
sessed the safety and efficacy of BEV alone or combined with 
irinotecan in 39 patients with recurrent grade II/III gliomas. 
 Results: Both BEV monotherapy and its combination with 
irinotecan were well tolerated. Response rates were 26% as 
monotherapy and 33% in combination using Macdonald 
and RANO criteria. The median PFS was 4.2 months and the 
PFS rate at 6 months 29% for BEV alone, and 4.7 months and 
42% for the combination. The median overall survival was 
14.8 months for BEV monotherapy and 8.1 months for the 
combination. Outcome after failure of BEV was better when 
patients continued BEV beyond progression.  Conclusion: 
BEV has limited activity in recurrent grade II/III gliomas. The 
additional value of irinotecan remains questionable. Pro-
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glioblastoma in uncontrolled phase II trials, leading to its 
registration in the USA and other countries  [4, 5] . Despite 
concerns regarding the lack of durable responses and the 
failure to demonstrate of an overall survival (OS) benefit, 
the use of BEV in recurrent glioma has widely spread to 
other glioma entities. This may be due to beneficial ef-
fects of BEV on performance status and steroid use  [6] 
and the apparent lack of alternative options after the fail-
ure of alkylating agent therapy.
 The role of BEV alone or in combination with irinote-
can in recurrent grade II and III gliomas has been less 
well studied than in glioblastoma, particular in Europe. 
We here report a retrospective analysis on the safety and 
efficacy of BEV alone or in combination with irinotecan 
in patients with recurrent grade II and III gliomas.
 Patients and Methods 
 We reviewed the reports of 39 unselected patients with grade 
II and grade III gliomas from three institutions (Heidelberg, Zu-
rich, St. Gallen) who received BEV for progressive or recurrent 
disease either as a single agent or in combination with irinotecan 
between 2007 and 2011. BEV was commonly administered at 10 
mg/kg, and irinotecan at 125 mg/m 2 without use of enzyme-in-
ducing antiepileptic drugs and at 340 mg/m 2 with use of enzyme-
inducing antiepileptic drugs, both at 2-weekly intervals. Radio-
logical response to BEV-based therapy was formally re-evaluated 
using both Macdonald and RANO criteria  [7, 8] for this analysis 
at the sites without a post hoc central review. Clinical benefit was 
defined by an improvement or stabilization of clinical symptoms, 
improvement of Karnofsky performance score (KPS) of  6 10, or 
reduction of steroid use. The assessment of adverse events was 
restricted to the period of BEV therapy. Toxicity data were col-
lected retrospectively using NCI common toxicity criteria (ver-
sion 4.0).
 PFS and OS rates were calculated from the first dose of BEV 
until progression and death. Survival after progression under 
BEV was assessed from the date of progression until death. Pro-
gression and death did not occur before the arbitrarily chosen 
cut-off date of October 1, 2011 in 5 and 14 patients, respectively. 
These patients were censored at this cut-off date. One patient was 
lost to follow-up before the cut-off date and was censored at the 
last date of MRI assessment. Data were analyzed by the Kaplan-
Meier estimation method and statistical significance was deter-
mined by log-rank test (Mantel-Cox) using the software of Graph-
Pad Prism software version 5.0 (San Diego, Calif., USA).
 Results 
 Study Population and Pretreatment Characteristics 
 Detailed patient characteristics are summarized in  ta-
ble  1 . 39 patients were identified: all patients had been 
pretreated with temozolomide and some patients also 
with nitrosourea-based chemotherapy. All but 1 patient 
had received radiotherapy. Another patient with an ex-
tensive grade II glioma, previously treated with temo-
zolomide, opted against radiotherapy. The median num-
ber of relapses before the administration of BEV-based 
regimens was 3 in the monotherapy group and 4.5 in the 
combination group. It was 4 for grade II tumors and 3 for 
grade III tumors.
 Treatment 
 27 patients, 14 with grade II and 13 with grade III gli-
oma and a median KPS of 80 were treated with BEV 
alone, and 12 patients, 7 with grade II and 5 with grade 
III glioma and a median KPS of 90 received BEV in com-
bination with irinotecan. The duration of BEV treatment 
was 3.6 months for monotherapy and 4.5 months with the 
combination ( table 2 ). Interruption of therapy for more 
than 4 weeks occurred in 6 of 39 patients because of pa-
tients’ or physicians’ decisions.
 Toxicity 
 Both BEV monotherapy and BEV in combination with 
irinotecan were generally well tolerated ( table 3 ). Arterial 
hypertension was a common adverse event with an over-
all incidence of 26% in the monotherapy and 33% in the 
combination group. Grade 4 leukopenia was observed in 
1 patient only. No thromboembolic events or hemorrhag-
es were reported.
 Outcome 
 Some clinical benefit was noted in more than half of 
the patients ( table 2 ). A KPS increase of 10% was seen in 
14.8% of patients with BEV alone and 8.3% of patients 
with BEV in combination. No patient had an increase in 
KPS of 20% or more. 26% of the patients in the BEV 
monotherapy and 33% in the combination group achieved 
a partial response (PR) as assessed by Macdonald and by 
RANO criteria ( table 2 ). The median duration of the best 
response was 3.9 months in the monotherapy group and 
3.5 months in the combination group.
 The PFS was different in 1 patient when using RANO 
criteria instead of Macdonald criteria. It was progressive 
disease instead of stable disease because of a progressive 
FLAIR lesion. In this patient, PFS by RANO was consid-
ered to be valid by the site and entered into our database. 
The comparison of PFS and OS between BEV monother-
apy and combination with irinotecan did not indicate 
major differences either for all patients pooled or sepa-
rated by grade or histology ( fig. 1 ;  table 2 ). For the grade 
II and III tumors pooled, the median PFS was 4.2 months 
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Table 1. P atient characteristics
BEV monotherapy BEV + irinotecan
Glioma grade: II (n = 14) III (n = 13) II + III (n = 27) II (n = 7) III (n = 5) II + III (n = 12)
Histology, n (%)
Astrocytic 10 (71) 6 (46) 16 (59) 6 (86) 3 (60) 9 (75)
Oligoastrocytic 2 (14) 3 (23) 5 (19) 1 (14) 2 (40) 3 (25)
Oligodendroglial 2 (14) 4 (31) 6 (22) 0 (0) 0 (0) 0 (0)
Median age (range), years 32 (19–51) 43 (15–67) 38 (15–67) 25 (20–34) 38 (28–55) 29 (20–55)
Gender, n (%)
Male 9 (64) 7 (54) 16 (59) 4 (57) 4 (80) 8 (67)
Female 5 (36) 6 (46) 11 (41) 3 (43) 1 (20) 4 (33)
Extent of surgery at diagnosis, n (%)
Biopsy 8 (57) 3 (23) 11 (41) 0 (0) 1 (20) 1 (8)
Resection 6 (43) 10 (77) 16 (59) 7 (100) 4 (80) 11 (92)
Previous radiotherapy, n (%) 14 (100) 13 (100) 27 (100) 6 (86) 5 (100) 11 (92)
Previous chemotherapy, n (%)
Temozolomide 14 (100) 13 (100) 27 (100) 7 (100) 5 (100) 12 (100)
Nitrosourea-based 11 (79) 5 (38) 16 (59) 4 (57) 4 (80) 8 (67)
Other 1 (7) 0 (0) 1 (4) 1 (14) 0 (0) 1 (8)
Surgery at relapse, n (%) 10 (71) 4 (31) 14 (52) 7 (100) 5 (100) 12 (100)
Prior to relapse treated with BEV 2 (14) 0 (0) 1 (7) 0 (0) 2 (40) 2 (17)
Higher histological grading 9 (64) 0 (0) 10 (37) 4 (57) 1 (20) 5 (42)
Contrast-enhancing tumor prior to
therapy with BEV, n (%) 14 (100) 13 (100) 27 (100) 7 (100) 4 (80) 11 (92)
Median time from diagnosis to start with
BEV, months 105 56 71 117 91 104
Median number of relapses prior to BEV
(range) 4 (1–6) 2 (2–9) 3 (1–9) 5 (1–6) 4 (3–6) 4.5 (1–6)
Median KPS prior to BEV (range), % 80 (50–100) 80 (50–100) 80 (50–100) 90 (70–100) 90 (70–90) 90 (70–100)
Table 2. R esponse assessment and outcome
BEV monotherapy BEV + irinotecan
Glioma grade: II (n = 14) III (n = 13) II + III (n = 27) II (n = 7) III (n = 5) II + III (n = 12)
Duration of BEV, months
Median
Range
3.7
0.9–16.5
3.6
0.4–14.6
3.6
0.4–16.5
3.9
1.4–14
7
2.9–29
4.5
1.4–36.8
Best response, n (%)
Macdonald [7]
PR 3 (21) 4 (31) 7 (26) 3 (43) 1 (20) 4 (33)
Stable disease 6 (43) 3 (23) 9 (33) 2 (29) 4 (80) 6 (50)
Progressive disease 5 (36) 6 (46) 11 (41) 2 (29) 0 (0) 2 (17)
RANO [8]
PR 3 (21) 4 (31) 7 (26) 3 (43) 1 (20) 4 (33)
Stable disease 6 (43) 2 (15) 8 (30) 2 (29) 4 (80) 6 (50)
Progressive disease 5 (36) 7 (54) 12 (44) 2 (29) 0 (0) 2 (17)
Median duration of best response
months 4.8 2.6 3.9 3.0 4.1 3.5
Clinical benefit, % 64 62 63 43 60 50
Median PFS, months 4.2 3.3 4.2 3.8 8.1 4.7
PFS-6, % 33 25 29 29 60 42
Median OS, months 14.4 7.4 14.8 8.1 18.5 8.1
OS at 12 months, % 50 40 44 29 60 42
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and the PFS rate at 6 months (PFS-6) was 29% for BEV 
alone. For the combination, median PFS was 4.7 months 
and PFS-6 was 42%. The median OS was 14.8 months and 
the OS at 12 months 44% for BEV alone and 8.1 months 
and 42% with BEV + irinotecan. Data split by histology 
are provided in  table  2 . Overall, median PFS was 4.2 
months and PFS-6 32% for patients with grade II tumors 
and 4.9 months and 35% for patients with grade III tu-
mors. OS was 9.9 months for grade II and 14.8 months for 
grade III tumors.
 We further analyzed the outcome after progression 
under BEV to evaluate whether the discontinuation of 
BEV may have affected survival. 31 patients were avail-
able for that analysis since those patients had progressive 
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 Fig. 1.  Kaplan-Meier plots for PFS (left) and OS (right) for patients with grade II and grade III gliomas pooled 
( a ), grade II gliomas only ( b ), or grade III gliomas only ( c ) receiving BEV alone or BEV + irinotecan. 
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disease under BEV until the indicated cut-off date. BEV 
was continued as a monotherapy or in any combination 
therapy in 15 patients while BEV was stopped in 16 pa-
tients. Up to failure, treatment duration with BEV was 16 
weeks in those who continued as opposed to 15 weeks in 
those who did not. Median OS from progressive disease 
under BEV was 55 weeks with BEV versus 8.5 weeks with-
out BEV (p = 0.0022) ( fig. 2 ). Interestingly, only 1 patient 
out of 12 (8%) of the combination group continued a BEV-
containing regimen in contrast to 14 out of 27 (52%) pa-
tients in the monotherapy group. This may indicate a less 
favorable toxicity profile in the combination group. The 
observation that BEV was more likely to be continued 
when administered as a single agent may be one explana-
tion on the observed benefit on OS in the BEV mono-
therapy group.
 Discussion 
 This retrospective study confirms and extends the 
current knowledge on the safety and efficacy of BEV-
based therapy for progressive or recurrent gliomas of 
WHO grades II and III.  Table  4 provides an overview 
about the current literature available on this topic. In line 
with previous data, BEV was well tolerated with hyper-
tension as a known risk to take care of  [9] . An increased 
toxicity with the addition of irinotecan did not become 
apparent in this small patient population. However, the 
toxicity data have to be interpreted with caution since ret-
rospective studies tend to underestimate toxicity.
 Based on the perception that BEV has mainly an effect 
on contrast-enhancing tumor, the activity of BEV in low-
grade tumors may be limited. However, previous reports 
as well as our current study suggest at least moderate ac-
tivity for BEV in recurrent grade II and grade III gliomas. 
This may be due to a high proportion of secondary ma-
lignant progression of the tumor. In our series, all but 1 
patient had contrast-enhancing tumor prior to institu-
tion of BEV, and progression to a higher histological 
grading was common in patients undergoing second sur-
gery. Patients with grade II tumors had a higher median 
number of treatments for relapse or progression than pa-
tients with grade III tumors prior to BEV (4 vs. 3). This 
may explain the apparent lack of a difference in outcome 
from BEV by tumor grade in this series.
 Response rates and data for PFS and OS ( table 2 ) are 
comparable with previously published results ( table  4 ). 
The retrospective nature of this study limits the reliability 
of our data on clinical benefit, but at least half of the pa-
tients appeared to have improved with BEV, albeit tran-
siently. Chamberlain and Johnston  [10, 11] reported retro-
spective data of patients with recurrent anaplastic astro-
cytoma (n = 25) and anaplastic oligodendroglioma (n = 
22) treated with BEV as a single agent with a PFS-6 of 60 
and 68% and a median OS of 9 and 8 months. However, a 
prospective study evaluating BEV as a single agent in 31 
patients with recurrent anaplastic glioma did not meet the 
primary endpoint of a PFS-6 of 50%  [12] . Desjardins et al. 
Table 3. T oxicity
BEV monotherapy
 (n = 27)
BEV + irinotecan
 (n = 12) 
CTC grade CTC grade
1/2 3/4 total (%) 1/2 3/4 t otal (%)
Non-hematologic
Hypertension 6 1 7 (26) 4 0 4 (33)
Nausea 0 0 0 (0) 1 0 1 (8)
Anorexia 0 0 0 (0) 1 0 1 (8)
Allergy 1 0 1 (4) 0 0 0 (0)
Epistaxis 1 0 1 (4) 0 0 0 (0)
Infection 1 0 1 (4) 0 0 0 (0)
Hematologic
Anemia 2 0 2 (7) 0 0 0 (0)
Thrombocytopenia 2 2 4 (15) 2 0 2 (17)
Leukopenia 4 1 5 (19) 6 0 6 (50)
100
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0
0 50
Weeks after date of progression
100 150
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S 
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)
BEV continuation
BEV discontinuation
 Fig. 2. Outcome after failure of the first BEV-containing regimen. 
Kaplan-Meier plot for OS after failure of the first BEV-containing 
regimen showing the proportion of patients continuing on a BEV-
containing regimen (n = 15) versus patients discontinuing BEV
(n = 16). 
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 [13] reported modest activity for the combination of BEV 
with irinotecan (n = 33) with a PFS-6 of 55% and median 
OS of 15 months in a prospective phase II trial of recurrent 
anaplastic gliomas. This compares favorably with data 
from two similar but retrospective studies indicating PFS-
6 rates of 39% for a mixed population of anaplastic glioma 
and glioblastoma  [14] and 42% for grade II and grade III 
oligodendroglioma  [15] . Similarly, our retrospective data 
do not indicate an additional value of the combination 
therapy compared with BEV alone.
 Response assessments in the discussed studies were 
based on Macdonald criteria  [7] . Aware of possibly alter-
native patterns of progression during anti-angiogenic 
therapy especially regarding non-enhancing T2 and 
FLAIR tumor volume, we additionally determined re-
sponse rates using the new RANO criteria  [8, 14] . In 1 of 
39 patients, the use of the RANO criteria showed a differ-
ent result. Thus, the introduction of these novel criteria 
may alter response assessment and result in a change in 
treatment only in a minority of patients. The use of BEV 
in malignant glioma is often continued beyond progres-
sion because ill-defined rebound phenomena are feared. 
However, there is little evidence supporting the percep-
tion that withdrawing BEV is worse than continuing the 
drug after it has failed. In a small retrospective study, 
there was no significant difference in survival of high-
grade glioma patients after a BEV-free regimen compared 
to the continued use BEV (91 vs. 116 days)  [16] . Similarly, 
a recent meta-analysis of four phase II studies conducted 
in patients with recurrent grade III gliomas did not show 
a significant difference between BEV-containing or non-
containing salvage therapies after BEV failure for OS  [17] . 
Our retrospective analysis suggests a prolonged OS if 
BEV is continued beyond progression. However, the in-
terpretation of these data is difficult because the proba-
bility of a preselection of this patient population is high. 
The decision of continuing or withdrawing BEV is likely 
to have been influenced by clinical performance status, 
age, patients’ and physicians’ preferences. To address this 
question, a prospective trial design including randomiza-
tion of patients will be necessary.
 In conclusion, there is evidence that BEV has activity 
not only in recurrent glioblastoma but also in grade II and 
grade III glioma. The effect on OS remains uncertain. In 
recurrent grade II and grade III glioma, a prospective 
phase II randomized study evaluating the efficacy of BEV 
with or without temozolomide (TAVAREC, EORTC 
26091, NCT01164189) has started accrual. This trial and 
further prospective and randomized trial data will be 
needed for a better evaluation of the role of BEV as a sin-
gle agent and in combination with other agents in order 
to improve the limited therapeutic options for patients 
with recurrent gliomas failing radiotherapy and alkylat-
ing agent chemotherapy.
Table 4. R etrospective series and prospective phase II studies in anaplastic gliomas treated with BEV
First author
[Ref]
Trial design Patient diagnosis, n Regimen Median PFS
months (95% CI)
PFS-
6, % 
Median OS 
months (95% CI)
Chamberlain
2008 [10]
Retrospective Anaplastic astrocytoma
n = 25
BEV monotherapy 7 (4.5–9.5) 60 9.0 (6.6–11.4)
Chamberlain
2008 [11]
Retrospective Anaplastic 
oligodendroglioma, n = 22
BEV monotherapy 8.0 (7.0–9.0) 68 8.0 (6.3–9.7)
Kreisl
2009 [12]
Phase II, single-
arm, prospective
Anaplastic glioma
n = 31
BEV monotherapy 2.9 (2.0–4.9) 20.9 12 (6.1–22.8)
Norden
2008 [14]
Retrospective Anaplastic glioma, n = 21
glioblastoma, n = 33
High grade glioma, n = 1
BEV + irinotecan 
(85%), BEV + other 
chemotherapy (15%)
5.5 (4.1–6.5) 39 8.2 (6.4–14.1)
Taillibert
2009 [15]
Retrospective Oligodendrogliomas grade 
II and grade III, n = 25
BEV + irinotecan 4.6 (3.9–G) 42 Not been reached 
Desjardins
2008 [13]
Phase II, single-
arm, prospective
Anaplastic glioma
n = 33
BEV + irinotecan 6.9 (4.8–13.8) 55 14.9 (95% CI not 
indicated)
Reardon
2009 [18]
Phase II, single-
arm, prospective
Anaplastic glioma
n = 32
BEV + etoposide 5.5 (3.7–7.6) 41 14.5 (8.3–G)
Sathornsumetee
2010 [19]
Phase II, single-
arm, prospective
Anaplastic glioma
n = 32
BEV + erlotinib 5.4 (4.2–8.3) 44 16.4 (10.3–28.4)
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